Open AccessRecent Advancements in the Treatment of Rectal Gastrointestinal Stromal Tumor: In Era of Imatinib
Author(s) -
Hui Qu,
Zhiyue Xu,
Ying Ren,
ZeZhong Gong,
HyokJu Ri,
Fan Zhang,
HaoNan Kang,
Yang Xu,
Xin Chen
Publication year - 2022
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s352860
Subject(s) - gist , medicine , imatinib , stromal tumor , incidence (geometry) , gastrointestinal tract , imatinib mesylate , stromal cell , oncology , physics , myeloid leukemia , optics
Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumor of the gastrointestinal tract, with an annual incidence of 10-15 cases per million. However, rectal GIST has a low incidence, accounting for approximately 0.1% of all rectal tumors. The treatment of rectal GISTs is still controversial and the relative unified guidelines and consensus opinions are inadequate. Treatment is based primarily on the clinical experience of the physician. The widespread application of neoadjuvant imatinib therapy allows diversification of treatment, especially in the choice of surgical methods. Herein, we reviewed the most recent literature and summarized the new progress in rectal tumor treatment, with the aim of providing patients with more systematic and individualized therapeutic strategies.